Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 6/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ATG7 | O95352 | 2/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.30 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.30 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.30 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.30 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.30 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.30 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GALR3 | O60755 | 1/20 | 0.30 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14081712 | 1.00 | ADK (0.35) | ADKADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL4020271 | 0.90 | ALDH1A1 (0.35) | ADKXDHPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL13598728 | 0.90 | ALDH1A1 (0.35) | ADKXDHPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL13494110 | 0.88 | ADK (0.38) | ADKADORA2AATG7XDHPRKAB2 | |
| SCHEMBL16497062 | 0.87 | ADK (0.41) | ADKADORA2AATG7PRMT5XDH | |
| SCHEMBL13650036 | 0.86 | LMNA (0.30) | ALDH1A1MAPT | |
| SCHEMBL4020373 | 0.86 | XDH (0.34) | XDHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL16496534 | 0.85 | ADK (0.36) | ADKADORA2AATG7XDHPRKAB2 | |
| SCHEMBL13494103 | 0.83 | ADK (0.34) | ADKATG7XDHPRKAB2PRKAG1 | |
| SCHEMBL14081722 | 0.82 | ADORA2A (0.44) | ADKADORA2AADORA3PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010015637-A1 | NEW ANTIVIRAL MODIFIED NUCLEOSIDES | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| US-20090253648-A1 | Tricyclic-Nucleoside Compounds for Treating Viral Infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-08 | — | — | US | disclosed |
| US-7524825-B2 | Tricyclic-nucleoside compounds for treating viral infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20090048189-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. | 2009-02-19 | — | — | US | disclosed |
| US-7414031-B2 | 5-nitro-nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20060252715-A1 | Tricyclic-nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2006-11-09 | — | — | US | disclosed |
| US-20060111311-A1 | 5-nitro-nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048189-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | TYMP, PNP, NSUN2 | ADK 944/4885ADORA2A 334/4885ADORA3 537/4885 |
| US-20060111311-A1 | 5-nitro-nucleoside compounds for treating viral infections | PNP, NT5C3B, NSUN2 | ADK 596/4885ADORA2A 340/4885ADORA3 508/4885 |
| US-20060252715-A1 | Tricyclic-nucleoside compounds for treating viral infections | PNP, TYMP, NSUN2 | ADK 365/4885ADORA2A 145/4885ADORA3 165/4885 |
| US-20090253648-A1 | Tricyclic-Nucleoside Compounds for Treating Viral Infections | PNP, TYMP, NSUN2 | ADK 365/4885ADORA2A 145/4885ADORA3 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.